[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bronchial-asthma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bronchial-asthma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,45,65,90,114,130,153,175,201,230,259,281,307,345,385,411,431,451,474,501,525,545,563],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100643271","evaluation-of-clinical-effect-of-acupuncture-on-acute-exacerbation-of-bronchial-asthma-100643271",false,"NCT07632352","Evaluation of Clinical Effect of Acupuncture on Acute Exacerbation of Bronchial Asthma","Evaluation of Clinical Effect of Acupuncture on Acute Exacerbation of Bronchial Asthma Based on Biological Holography Theory","Inclusion Criteria:\n\n1. Patients meeting the Western medicine diagnostic criteria for acute exacerbation of bronchial asthma\n2. Aged ≥ 18 years old\n3. Voluntarily receive treatment and sign the informed consent form\n\nExclusion Criteria:\n\n1. Those who fail to meet the inclusion criteria\n2. Patients suffering from other severe systemic diseases such as diseases of the circulatory system, hematological system and nervous system\n3. Pregnant or lactating women\n4. Subjects enrolled but not treated per the study protocol\n5. Patients who have participated in other clinical trials of medicinal products within 3 months\n6. Other circumstances deemed ineligible for enrollment by researchers","ALL","18 Years",{"count":19,"type":20},72,"ESTIMATED","INTERVENTIONAL",[23],"NA","Based on the bioholographic theory, this study preliminarily explores the clinical efficacy of hand acupuncture in treating acute exacerbation of bronchial asthma and evaluates its immediate anti-asthmatic effect, so as to provide a new therapeutic strategy for the clinical management of bronchial asthma.",[26],"Bronchial Asthma",[28,29,30,31],"bronchial asthma","acute exacerbation","Biological holography theory","Acupuncture","RECRUITING","2026-06-02",{"date":35,"type":36},"2026-06-08","ACTUAL",{"date":38,"type":36},"2025-04-15",{"date":40,"type":20},"2027-01-01",{"name":42,"class":43},"Henan University of Traditional Chinese Medicine","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":60,"completionDateStruct":61,"leadSponsor":63,"locationsCount":44},"100640865","n95-masks-for-lung-health-while-golfing-during-wildfire-season-100640865","NCT07620691","N95 Masks for Lung Health While Golfing During Wildfire Season","A Pilot \u002F Feasibility Study on Cardiorespiratory Health of Golfers During Wildfire Season","Inclusion Criteria:\n\n* Golf on a regular basis (two or more times per week)\n\nExclusion Criteria:\n\n* Smoker",true,{"count":54,"type":20},40,[23],"Lung health is negatively affected during wildfire season by increased smoke pollution. Wearing N95 masks protects lung health in the short-term. The purpose of our study is to assess whether wearing of N95 facemasks on days with moderate to high air pollution in people who go outside to golf on a regular basis (two or more times per week) for two months during the wildfire season projects lung health.",[26],"2026-05-26",{"date":33,"type":36},{"date":58,"type":36},{"date":62,"type":20},"2026-12-31",{"name":64,"class":43},"University of Saskatchewan",{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":52,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":74,"phases":4,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":88,"locationsCount":44},"100374584","pulmonary-condensate-non-invasive-evaluation-of-pulmonary-involvement-in-asthma-and-cystic-fibrosis-100374584","NCT04157361","Pulmonary Condensate: Non-invasive Evaluation of Pulmonary Involvement in Asthma and Cystic Fibrosis.","Pulmonary Condensate: A Promising Source of Proteomic Biomarkers for Non-invasive Evaluation of Pulmonary Involvement in Asthma and Cystic Fibrosis.","Inclusion Criteria:\n\n* Children\u002Fadults with moderate or IgE mediated asthma\n* Children\u002Fadults with cystic fibrosis\n* Healthy control children\u002Fadults without lung disorders\n\nExclusion Criteria:\n\n\\-",{"count":73,"type":20},450,"OBSERVATIONAL","Exhaled breath condensate (EBC) represents a rich source for countless biomarkers that can provide valuable information about respiratory as well as systemic diseases. Finding non-invasive methods for early detection of lung injury, inflammation and infectious complications in chronic diseases like (CF) Cystic fibrosis or (AB) Bronchial asthma would be highly beneficial. Investigators propose to establish EBC \"breathprints\" revealing molecular signatures of pulmonary inflammation and specific respiratory bacterial infections of CF patients and AB. Investigators hypothesize that the analysis of EBC can reveal biomarkers specific for severity of the inflammation, and infection caused by opportunistic pathogens such as P. aeruginosa (PA). With these breath-prints, investigators also propose to establish correlations between respiratory microbiota using traditional methods and CF lung disease severity. Together, the studies will advance the development and validation of EBC as a novel tool for the proper diagnosis of AB and monitoring of CF disease activity, treatment efficacy and PA or another opportunistic infections.",[26,77],"Pulmonary Cystic Fibrosis",[79,80,81],"Breath condensate","Bronchial asthma","Cystic Fibrosis","2026-03-19",{"date":84,"type":36},"2026-03-23",{"date":86,"type":36},"2015-05-01",{"date":62,"type":20},{"name":89,"class":43},"The Institute of Molecular and Translational Medicine, Czech Republic",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":21,"phases":100,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":44},"100618082","phase-2-safety-and-efficacy-of-pa9159-inhalation-aerosol-for-the-treatment-of-adult-bronchial-asthma-100618082","NCT07326995","Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma","A Phase 2 Clinical Study to Evaluate the Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma","Inclusion Criteria:\n\n* Aged 18 to 75 years inclusive, regardless of gender;\n* According to the definition in the Chinese \"Guidelines for Prevention and Treatment of Bronchial Asthma (2020 Edition),\" subjects diagnosed with bronchial asthma, including those with an initial diagnosis of asthma, or those diagnosed with asthma during childhood or adolescence with stable condition who have not received long-term treatment but exhibit significantly more pronounced symptoms in adulthood and\u002For recently compared to the past;\n* Pre-randomization, pulmonary function tests show 60% ≤ FEV1% predicted ≤ 85%;\n* Any objective test result indicating variable airflow limitation conducted within 1 year prior to screening is positive, or the bronchodilator test during the screening period is positive, i.e., an increase in FEV1 ≥ 12% and an absolute increase in FEV1 ≥ 200 mL 15-30 minutes after inhaling 400 μg salbutamol (if the bronchodilator test result does not meet the positive threshold, a repeat bronchodilator test is allowed within 14 days after the test \\[excluding the test day\\]); or the bronchial provocation test is positive, i.e., a decrease in FEV1 ≥ 20% after inhaling a provocant (methacholine or histamine); or the average daily diurnal variability of peak expiratory flow (PEF) (calculated as the sum of daily PEF diurnal variability over 7 consecutive days divided by 7) \\> 10%;\n* Voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* Subjects who are unable to correctly use a nebulizer, cannot tolerate nebulized inhalation administration, or fail inhalation administration training;\n* Subjects with other pulmonary diseases, including chronic obstructive pulmonary disease, bronchiectasis, pulmonary fibrosis, tuberculosis, etc., for which, in the investigator's judgment, asthma remains the dominant condition;\n* Coexistence of other clinically significant conditions that may affect lung function, including but not limited to pleural diseases, mediastinal diseases, diaphragmatic disorders, myasthenia, thoracic deformities, etc.;\n* History of severe cardiovascular diseases, such as congestive heart failure, coronary artery disease, myocardial infarction, arrhythmia, uncontrolled hypertension (resting seated systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg on two or more consecutive measurements), etc., which, in the investigator's judgment, would put the subject at risk or may affect the interpretation of study results;\n* Subjects with hyperthyroidism, assessed by the investigator as unsuitable for participation in this trial;\n* History of severe hematologic, hepatic, psychiatric, renal, or other diseases that, in the investigator's judgment, would put the subject at risk or may affect the interpretation of study results;\n* History of malignancy within the past five years (excluding cured cervical intraepithelial neoplasia, thyroid cancer, or basal cell carcinoma of the skin diagnosed and cured within 5 years);\n* Subjects who have undergone or are expected to undergo solid organ or bone marrow transplantation within the next year;\n* Hypokalemia (serum potassium \\\u003C 3.5 mmol\u002FL during screening);\n* Type I diabetes or poorly controlled Type II diabetes (fasting blood glucose \\> 11.1 mmol\u002FL during screening);\n* Known or pre-randomization examination revealing oral, pharyngeal, or esophageal candidiasis;\n* Abnormal liver or kidney function during screening (ALT and\u002For AST \\> 2× upper limit of normal; Scr \\> 1.5× upper limit of normal);\n* Positive hepatitis B surface antigen or hepatitis B core antibody with HBV DNA ≥ 2000 IU\u002FmL, positive hepatitis C antibody with HCV RNA ≥ 1000 IU\u002FmL, positive human immunodeficiency virus antibody, or history of acquired immunodeficiency syndrome;\n* Known allergy to any component of inhaled corticosteroids or salbutamol preparations;\n* Respiratory tract infection, sinus infection, or acute otitis media within 4 weeks before screening or during the run-in period, which, in the investigator's judgment, would lead to changes in asthma treatment or affect the subject's asthma status;\n* Asthma exacerbation requiring systemic corticosteroid treatment within 4 weeks before screening or during the run-in period, or asthma requiring oral corticosteroid therapy, or other conditions requiring systemic corticosteroid treatment;\n* Use of strong CYP3A4 enzyme inhibitors (e.g., ritonavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin, etc.) within 4 weeks before dosing, or need for concomitant use of strong CYP3A4 inhibitors during the trial;\n* Smoking cessation \\\u003C 1 year at screening (including cigarettes, cigars, pipe tobacco, e-cigarettes, etc.), or previous smoking history \\> 10 pack-years \\[pack-years = number of packs per day × years of smoking, where 1 pack = 20 cigarettes\\];\n* History of drug abuse, substance abuse, or alcoholism within 2 years before screening \\[alcoholism defined as average daily alcohol intake \\> 2 units (1 unit = 360 mL beer, or 45 mL of 40% alcohol liquor, or 150 mL wine)\\];\n* Pregnant or lactating women, or women planning pregnancy during the trial;\n* Subjects who have participated in other clinical trials within 1 month before screening;\n* Any other reason considered by the investigator to make the subject unsuitable for participation in the trial.","75 Years",{"count":99,"type":20},60,[101],"PHASE2","PA9159 is a highly potent novel corticosteroid. The purpose of this study is to evaluate the safety, efficacy and characteristics of population pharmacokinetics of multiple dosing of PA9159 Inhalation Aerosol in patients with bronchial asthma.",[26],"2025-12-24",{"date":106,"type":36},"2026-01-08",{"date":108,"type":36},"2025-02-24",{"date":110,"type":20},"2026-03",{"name":112,"class":113},"Anhui Palo Alto Pharmaceuticals, Inc.","INDUSTRY",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":97,"enrollmentInfo":119,"targetDuration":4,"studyType":21,"phases":121,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":129,"locationsCount":44},"100617906","phase-2-study-on-the-safety-and-efficacy-of-pa9159-inhalation-aerosol-for-the-treatment-of-adult-bronchial-asthma-100617906","NCT07324707","Study on the Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma",{"count":120,"type":20},30,[101],"PA9159 is a highly potent novel corticosteroid. The purpose of this study is to evaluate the safety, efficacy and characteristics of population pharmacokinetics of multiple dosing of PA9159 Inhaler in patients with bronchial asthma.",[26],{"date":125,"type":36},"2026-01-07",{"date":127,"type":36},"2025-10-15",{"date":110,"type":20},{"name":112,"class":113},{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":52,"sex":16,"minAge":137,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":21,"phases":139,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":144,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":151,"locationsCount":44},"100610767","phase-1-bioequivalence-study-of-aju-r713-and-r713r-in-healthy-adult-volunteers-100610767","NCT07231861","Bioequivalence Study of AJU-R713 and R713R in Healthy Adult Volunteers","An Open-Label, Randomized, Fasting, Single-Dose, Two-Sequence, Two-Period Crossover Study to Evaluate the Bioequivalence of \"AJU-R713\" and \"R713R\" in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Healthy adults aged 19 years or older at the time of screening.\n* Body mass index (BMI) between 18 and 30 kg\u002Fm².\n\n  * Male subjects: body weight ≥ 50 kg.\n  * Female subjects: body weight ≥ 45 kg.\n* Clinically healthy based on medical history, physical examination, vital signs, electrocardiogram (ECG), and laboratory test results, as determined by the investigator.\n* Willing and able to provide written informed consent after receiving a full explanation of the study.\n* Subjects (and their partners, if applicable) agree to use highly effective, non-hormonal contraception from the first dosing day until one week after the last dose.\n\nExclusion Criteria:\n\n* Use of drugs known to induce or inhibit drug-metabolizing enzymes within 30 days prior to the first dose, or any medication likely to interfere with the study within 10 days prior to dosing.\n* Participation in any clinical trial involving investigational products within 6 months prior to the first dose.\n* Whole blood donation within 8 weeks, or component blood donation within 2 weeks prior to the first dose.\n* History of gastrointestinal surgery that may affect drug absorption (excluding appendectomy and hernia repair).\n* Known hypersensitivity to the investigational product or its components.\n* Known metabolic or genetic disorders such as galactose intolerance, lactase deficiency, glucose-galactose malabsorption, or phenylketonuria.\n* History of clinically significant psychiatric illness.\n* Pregnant or breastfeeding women, or women with a possibility of pregnancy.","19 Years",{"count":99,"type":20},[140],"PHASE1","To Evaluate the Safety and Pharmacokinetics of Pranlukast hydrate in Healthy Adults.",[26,143],"Perennial Allergic Rhinitis","NOT_YET_RECRUITING","2025-11-16",{"date":147,"type":36},"2025-11-19",{"date":149,"type":20},"2025-12",{"date":149,"type":20},{"name":152,"class":113},"AJU Pharm Co., Ltd.",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":160,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":74,"phases":4,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":144,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":4},"100610694","impact-of-comorbidities-some-biomarkers-micro-rna-in-childhood-asthma-phenotypes-100610694","NCT07230912","Impact of Comorbidities, Some Biomarkers, Micro RNA in Childhood Asthma Phenotypes","Impact of Comorbidities, Some Biomarkers, Micro RNA in Childhood Asthma Phenotypes, Severity and Response to Therapy","Inclusion Criteria:\n\n* Children aged 6-12 years diagnosed asthma, inpatient or attending pediatric outpatient clinic of Assiut university children hospital.\n\nExclusion Criteria:\n\n* \\- Chronic respiratory illness other than asthma (e.g., bronchiectasis, CF)\n* Known immunodeficiency or systemic illness\n* patients with skeletal deformities\n* patients suspected inborn errors of metabolism","6 Years","12 Years",{"count":163,"type":20},82,"* Assess response to treatment in children with bronchial asthma attending Assiut university children hospital.\n* Role of comorbidities in controlling symptoms of bronchial asthma.\n* Evaluate the role of the soluable interleukin 5 receptor, I C-telopeptide of type I collagen (ICTP), miR-223-3p and miR-191-5p in bronchial asthma.",[26],"2025-11-13",{"date":168,"type":36},"2025-11-17",{"date":170,"type":20},"2025-12-30",{"date":172,"type":20},"2027-02-28",{"name":174,"class":43},"Assiut University",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":21,"phases":183,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":44},"100607061","adherence-to-inhaled-therapy---a-globally-overlooked-problem-in-patients-with-chronic-obstructive-pulmonary-disease-and-bronchial-asthma-100607061","NCT07183657","Adherence to Inhaled Therapy - a Globally Overlooked Problem in Patients With Chronic Obstructive Pulmonary Disease and Bronchial Asthma","PATIENTS\n\nInclusion Criteria:\n\n1. signed informed consent,\n2. age ≥ 18 years,\n3. previously diagnosed BA\u002FCOPD meeting GOLD 2024 and GINA 2024 diagnostic criteria,\n4. ability to cooperate,\n5. at least 8 weeks without exacerbation,\n6. use of a particular inhaler for at least 3 months.\n\nExclusion Criteria:\n\n1. pre-terminal\u002Fterminal stage of any disease,\n2. uncooperative patient,\n3. significant limitation of mobility or cognitive functions.\n\nHEALTHCARE PROFESSIONALS\n\nInclusion Criteria:\n\n1. signed informed consent,\n2. completed education in medicine, pharmacy, or nursing,\n3. more than one year of working experience,\n4. care for patients taking inhaled therapy for BA\u002FCOPD.",{"count":182,"type":20},1000,[23],"Comprehensive assessment and interventions to promote adherence to inhaled therapy in patients with bronchial asthma and chronic obstructive pulmonary disease involving health care professionals caring for these patients in different settings and using the Five Steps Assessment tool and artificial intelligence methods and tools.",[186,26],"Chronic Obstructive Pulmonary Disease (COPD)",[186,188,189,80,190,191],"Intervention","Mobile Application","Adherence","Inhaled therapy","2025-09-25",{"date":194,"type":36},"2025-09-30",{"date":196,"type":36},"2025-06-03",{"date":198,"type":20},"2028-12-31",{"name":200,"class":43},"Charles University, Czech Republic",{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":21,"phases":211,"briefSummary":212,"conditions":213,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":44},"100604810","community-exercise-treating-effect-on-cardiopulmonary-disease-patients-100604810","NCT07154355","Community Exercise Treating Effect on Cardiopulmonary Disease Patients","Clinical Study Protocol on the Impact of Community-Based Exercise Training on the Exercise Capacity of Patients With Reduced Cardiovascular and Pulmonary Function","Inclusion Criteria:\n\n1. Patients aged 18 to 85 with abnormal pulmonary or cardiovascular function.\n2. Individuals who have completed a medical screening form to confirm they are free from illnesses and prescription medications that could impair their ability to complete the required testing and fitness training.\n3. Participants who did not engage in structured, systematic moderate-to-intense strength or endurance training during the study period (specifically, not within the previous year).\n4. At the onset of the trial, participants were physically active but had never participated in formal exercise more than twice a week.\n\nExclusion Criteria:\n\n1. Patients with neuromuscular or skeletal disorders, or systemic diseases such as diabetes, cancer, or heart disease.\n2. Individuals using medications known to affect health or the interpretation of study results.\n3. Participants who have engaged in organized, systematic endurance or strength training of moderate to high intensity within the past year.\n4. Patients who decline to participate in the study.\n5. Other medical conditions or states that render exercise training inappropriate.","85 Years",{"count":210,"type":20},200,[23],"The goal of this clinical trial is to learn if community-based exercise training can benefit patients aged 18 to 85 with diminished cardiovascular and pulmonary function. The main aim of this study is:\n\n• Establish a community or home-based fitness training program for patients with cardiopulmonary insufficiency to improve adherence, safety, and efficacy while alleviating the burden on both patients and society.\n\nResearchers will compare community-based exercise training to non-exercise training to see if community-based exercise training works to improve cardiovascular and pulmonary function.\n\nParticipants will:\n\n* Engage in community or home exercise training for 40-60 minutes, five times weekly, during a duration of eight weeks. Exercise modalities are primarily determined by the patients' individual preferences and habits, such as brisk walking, running, swimming, cycling, and hiking.\n* Adjust the exercise intensity according to their cardiopulmonary exercise test and the person's perceived exertion level.\n* Utilize fitness bracelets or watches to document statistics during workouts and submit them to the experimenter weekly, covering the five days of exercise within that week.\n* refrain from making any dietary modifications throughout the trial.",[214,215,216,217,26,218,219,220],"Coronary Heart Disease (CHD)","Heart Failure","Cardiomyopathy","COPD","Respiratory Failure","Thoracic Tumors","Cardiopulmonary Diseases","2025-08-26",{"date":223,"type":36},"2025-09-04",{"date":225,"type":36},"2025-01-30",{"date":227,"type":20},"2030-12",{"name":229,"class":43},"Guangdong Provincial People's Hospital",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":74,"phases":4,"briefSummary":238,"conditions":239,"keywords":245,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":44},"100597560","the-use-of-entropy-to-assess-sleep-disordered-breathing-in-chronic-respiratory-disease-100597560","NCT07060079","The Use of Entropy to Assess Sleep Disordered Breathing in Chronic Respiratory Disease","Inclusion Criteria:\n\n* All adult patients (≥ 18years) with chronic respiratory disease with\u002Fwithout SDB.\n* patients who have had previously negative studies as a control group.\n* Subject is able to read, understand, and sign the informed consent form.\n* Willing to sleep with portable monitoring devices.\n\nExclusion Criteria:\n\n* Patients who are under 18 years of age at the time of the index study.\n* Contraindications to the use of portable monitoring.\n* Inability to give informed consent to take part in the study.",{"count":237,"type":20},120,"Research is being conducted into chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD), asthma, interstitial lung disease, and bronchiectasis. The investigation specifically focuses on sleep-disordered breathing (SDB) in individuals with chronic respiratory disease. SDB encompasses a range of conditions, the most common of which is obstructive sleep apnoea. In obstructive sleep apnoea, periodic pauses in breathing (apnoea) lead to reduced blood oxygen levels. To detect these events, patients typically undergo sleep studies that involve monitoring oxygen saturation, heart rate, and respiratory patterns during sleep. When chronic respiratory disease and SDB coexist, breathing disturbances during sleep may be exacerbated.\n\nTo identify SDB, sleep studies are commonly used to assess oxygen levels, heart rate, and breathing patterns. The objective of this research is to identify differences between patients with chronic respiratory diseases who have SDB and those who do not. This will be achieved by analysing sleep study data using a novel analytical approach. The aim is to determine whether this method can yield more detailed insights into the underlying pathophysiology of these conditions.",[26,240,241,217,242,243,244],"Bronchiectasis","ILD","OSAHS","OSA","Obesity Hypoventilation Syndrome (OHS)",[246,241,247,248,217,249],"SDB","Entropy","bronchiectasis","asthma","2025-07-08",{"date":252,"type":36},"2025-07-11",{"date":254,"type":36},"2025-04-30",{"date":256,"type":20},"2026-09-30",{"name":258,"class":43},"University College, London",{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":16,"minAge":266,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":21,"phases":269,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":144,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":44},"100584907","phase-3-a-trial-on-the-treatment-of-bronchial-asthma-with-budesonide-formoterol-combined-with-immune-modulators-staphylococcus-and-neisseria-tablets-100584907","NCT06895460","A Trial on the Treatment of Bronchial Asthma With Budesonide Formoterol Combined With Immune Modulators (Staphylococcus and Neisseria Tablets)","A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial on the Treatment of Bronchial Asthma With Budesonide Formoterol Combined With Immune Modulators (Staphylococcus and Neisseria Tablets)","Inclusion Criteria:\n\n1. Age ≥ 14 years, male or female;\n2. Confirmed diagnosis of asthma at least 6 months prior to screening;\n3. Patients with uncontrolled asthma (according to the 2024 GINA guidelines-asthma control level classification criteria, patients with partially controlled and uncontrolled asthma);\n4. Within the past 6 months, at least one of the following positive test results for lung function:\n\n   * Positive bronchodilator test with an increase in FEV1 of ≥12%, and an absolute increase in FEV1 of ≥200 ml;\n   * Positive bronchial provocation test or exercise challenge test;\n   * Peak expiratory flow (PEF) variability over 2 weeks with a daily variation rate of ≥20% or a weekly average variation rate of ≥10%;\n   * Significant improvement in lung function after 4 weeks of asthma treatment, with an increase in FEV1 of ≥12%, an absolute increase in FEV1 of ≥200 ml, or an improvement in PEF of ≥20%;\n5. Before the first administration of the study drug, the patient has good function of major organs and no contraindications to ICS + LABA treatment;\n6. The participant (or their legal representative) must sign and date the informed consent form, indicating their understanding of the study's purpose and the procedures involved, and their willingness to participate in the study.\n\nExclusion Criteria:\n\n1. Patients with a history of severe asthma (according to the definition in the Guidelines for the Prevention and Treatment of Bronchial Asthma (2024 Edition));\n2. Patients in the acute exacerbation phase who may require intravenous\u002Foral corticosteroids;\n3. Patients with rheumatology and immunology conditions;\n4. Atypical asthma or comorbidities such as pulmonary tuberculosis, chronic obstructive pulmonary disease, bronchiectasis, pulmonary embolism, severe respiratory failure, or other respiratory system diseases;\n5. Individuals with significant diseases other than bronchial asthma. Significant diseases are defined as conditions that, in the investigator's judgment, may place the participant at risk or affect the study results, such as severe cardiovascular, cerebrovascular, hepatic, renal, hematologic diseases, malignancies, psychiatric disorders, immune system diseases, or pulmonary organic functional impairments;\n6. Individuals allergic to the study drug or corticosteroids;\n7. Participation in another clinical trial within 30 days prior to screening or currently ongoing;\n8. Use of immune modulators (including thymosin, thymopeptides, interferon, transfer factor, Bacillus Calmette-Guérin polysaccharides, any type of bacterial extracts, such as Biostim, bacterial lysate capsules) within 30 days prior to the use of the study drug or during the study period;\n9. Women who are currently pregnant or breastfeeding, or women of childbearing potential who cannot use contraception during the study period;\n10. The participant is deemed unsuitable for study observation by the investigator.","14 Years",{"count":268,"type":20},198,[270],"PHASE3","A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial on the Treatment of Bronchial Asthma with Budesonide Formoterol Combined with Immune Modulators (Staphylococcus and Neisseria Tablets)",[26],{"date":274,"type":36},"2025-06-05",{"date":276,"type":20},"2025-06-20",{"date":278,"type":20},"2027-09-30",{"name":280,"class":43},"The First Affiliated Hospital with Nanjing Medical University",{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":11,"sex":16,"minAge":288,"maxAge":289,"enrollmentInfo":290,"targetDuration":4,"studyType":21,"phases":292,"briefSummary":293,"conditions":294,"keywords":4,"overallStatus":144,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":44},"100590969","effect-of-multimedia-protocol-about-asthma-control-100590969","NCT06974331","Effect of Multimedia Protocol About Asthma Control","Effect of Multimedia Protocol About Asthma Control on Asthmatic Children's Adaptation in the Era of Climate Changes","Inclusion Criteria:\n\n* Chronic asthmatic children (aged 7-11 years).\n* Both urban and rural asthmatic children.\n* Children and their mothers who have not received current or prior guidance about asthma control with the repercussions of climate changes.\n* Children whose mothers is educated.\n\nExclusion Criteria:\n\n* \\- Children with severe or acute asthma attacks as confirmed by a medical practitioner.\n* Any child suffering from other chronic disease or disability, as confirmed by a medical practitioner.","7 Years","11 Years",{"count":291,"type":20},70,[23],"This study aims to evaluate the effect of multimedia protocol about asthma control on asthmatic children's adaptation in the era of climate changes.",[26,295,296,297],"Childhood Asthma","Climate Change","Multimedia Learning Education","2025-05-08",{"date":300,"type":36},"2025-05-15",{"date":302,"type":20},"2025-07-01",{"date":304,"type":20},"2026-09-01",{"name":306,"class":43},"Mansoura University",{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":313,"eligibilityCriteria":314,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":315,"targetDuration":4,"studyType":74,"phases":4,"briefSummary":317,"conditions":318,"keywords":331,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":344},"100358354","the-role-of-concomitant-diseases-in-postoperative-complications-risk-stratification-100358354","NCT03945968","The Role of Concomitant Diseases in Postoperative Complications Risk Stratification.","The Role of Concomitant Diseases in Postoperative Complications Risk Stratification - a Prospective Observational Multi-center Cohort Study","STOPRISK","Inclusion Criteria:\n\n* surgical interventions on the abdominal organs,\n* 1-3 ASA physical status class\n\nExclusion Criteria:\n\n* the inability to assess the factors included in the study,\n* acute massive blood loss, aspiration,\n* bronchospasm,\n* anaphylactic reactions,\n* malignant hyperthermia",{"count":316,"type":20},16000,"Study is conducted to assess the prevalence and structure of comorbidity among patients undergoing abdominal surgery and produce the stratification of the risk of postoperative complications by identifying independent predictors for its development.",[319,320,26,321,322,323,324,325,326,327,328,329,330],"Coronary Heart Disease","Anemia","Stroke","Epilepsy","Parkinson's Disease","Heart Rhythm Disorders","Alzheimer's Disease","Neuromuscular Diseases","Diabetes","Chronic Heart Failure","Chronic Obstructive Pulmonary Disease","Chronic Kidney Diseases",[332,333,334],"anesthesia","concomitant diseases","risk stratification","2025-04-01",{"date":337,"type":36},"2025-04-04",{"date":339,"type":36},"2019-07-01",{"date":341,"type":20},"2026-02-28",{"name":343,"class":43},"Russian Federation of Anesthesiologists and Reanimatologists",38,{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":352,"enrollmentInfo":353,"targetDuration":4,"studyType":74,"phases":4,"briefSummary":355,"conditions":356,"keywords":370,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":44},"100556693","identification-of-multiple-pulmonary-diseases-using-volatile-organic-compounds-biomarkers-in-human-exhaled-breath-100556693","NCT06528418","Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath","Exploration and Study on the Identification of Various Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath","Inclusion Criteria:\n\n* Males or females, age must be 18 years old or above.\n* Patients must meet the CT imaging diagnostic criteria for different lung diseases, and patients must be able to provide electronic versions of CT image data.\n* Patients must have a clear clinical diagnosis.\n* All participants must sign a written informed consent form.\n\nExclusion Criteria:\n\n* Pregnant women.\n* Individuals with a history of cancer other than lung disease.\n* Individuals who have undergone organ transplants or non-autologous (allogeneic) bone marrow or stem cell transplants.\n* Individuals with other severe organic diseases or mental illnesses.\n* Individuals with metabolic diseases such as diabetes, hyperlipidemia, etc.\n* Any other condition that researchers deem unsuitable for participation in this clinical trial.","100 Years",{"count":354,"type":20},10000,"The goal of this observational study is to develop an advanced expiratory algorithm model utilizing exhaled breath volatile organic compound (VOC) marker molecules. This model aims to accurately diagnose mutiple pulmonary diseases. The primary objectives it strives to accomplish are:\n\n1. To assess the diagnostic accuracy of an exhaled breath VOC-assisted diagnostic artificial intelligence (AI) model in diagnose several common pulmonary diseases.\n2. To assess the diagnostic accuracy of an exhaled breath VOC-assisted diagnostic artificial intelligence (AI) model in diagnose more pulmonary diseases.",[357,358,217,359,360,361,362,363,364,365,366,367,26,240,368,369],"Lung Cancer","Lung Infection","Bronchitis","Pulmonary Fibrosis","Pulmonary Embolism","Pulmonary Arterial Hypertension","Pulmonary Tuberculosis","Pulmonary Abscess","Emphysema","Lung Injury","Cystic Fibrosis of the Lung","Interstitial Lung Disease","Preserved Ratio Impaired Spirometry",[371,372,373,374,375],"Pulmonary Disease","Volatile Organic Compounds","Human Exhaled Breath","micro Gas Chromatography-photoionisation","detector (μGC-PID) system","2025-03-23",{"date":378,"type":36},"2025-03-26",{"date":380,"type":36},"2024-06-30",{"date":382,"type":20},"2027-06-30",{"name":384,"class":113},"ChromX Health",{"id":386,"slug":387,"hasResults":11,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":4,"eligibilityCriteria":391,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":21,"phases":394,"briefSummary":395,"conditions":396,"keywords":398,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":410},"100581638","feno-detection-in-asthma-diagnosis-a-new-technology-approach-100581638","NCT06852911","FeNO Detection in Asthma Diagnosis: A New Technology Approach","The Diagnostic Significance of Exhaled Nitric Oxide (FeNO) With a Novel Technology in the Assessment of Bronchial Asthma","Patients:\n\nInclusion Criteria:\n\n1. Participants must be a minimum of 18 years of age, irrespective of gender;\n2. Individuals must possess a diagnosis of bronchial asthma that aligns with the international GINA 2023 diagnostic criteria;\n3. Respiratory symptoms must have been evident for at least 6 weeks;\n4. Participants should either have no history of smoking or have discontinued smoking for a period exceeding 5 years.\n\nExclusion Criteria:\n\n1. The concurrent use of additional asthma medications (such as glucocorticoids) alongside short-acting bronchodilators within the prior 4 weeks;\n2. A diagnosis of respiratory infection within the preceding 4 weeks;\n3. Conditions such as pregnancy, lactation, or menstruation;\n4. Participation in other clinical research studies;\n5. Any underlying medical or psychiatric conditions that, in the investigator's assessment, would render the individual unsuitable for participation in the study.\n\nHealthy:\n\nInclusion Criteria:\n\n1. Participants must be at least 18 years of age, with no restrictions on gender;\n2. Individuals should not have a history of allergic diseases or chronic respiratory conditions, and must not exhibit any significant abnormalities in health assessments conducted within the past year;\n3. There should be no acute illnesses or medication history within the preceding four weeks, and participants must not display any typical symptoms of respiratory infections;\n4. A history of smoking is not permitted, or individuals must have ceased smoking for a minimum of five years.\n\nExclusion Criteria:\n\n1. Individuals who are pregnant, breastfeeding, or currently experiencing menstruation;\n2. Those who have been on long-term medication;\n3. Participants involved in other clinical research studies;\n4. Any potential medical or psychological conditions that the researcher deems may render the subject unsuitable for participation in the study.",{"count":393,"type":20},170,[23],"The detection of exhaled nitric oxide (FeNO) represents a non-invasive, safe, and rapid approach for assessing endogenous nitric oxide (NO) levels within the airway. FeNO concentrations are closely associated with airway inflammation and hyperresponsiveness, and are currently recognized as biomarkers indicative of type II airway inflammation. Recent advancements in nitric oxide detection technology for both upper and lower airways, as well as for small and large airways, have provided significant insights for the diagnosis and management of conditions such as bronchial asthma, chronic cough, upper airway diseases, chronic obstructive pulmonary disease, and even rare airway disorders. Presently, FeNO measurement is frequently employed in the differential diagnosis and monitoring of airway inflammatory diseases.\n\nThe FeNO test is conducted using a FeNO test analyzer. Internationally, FeNO detection analyzers utilize three primary methodologies: chemiluminescence, laser, and electrochemical techniques. Among these, chemiluminescence is regarded as the \"gold standard\" globally. However, due to technical constraints, this methodology has not been clinically accessible within domestic settings. In China, the electrochemical FeNO analyzer is predominantly utilized, characterized by its compact size and portability. Nonetheless, this method necessitates patient cooperation during inhalation and exhalation, rendering it impractical for individuals who are unable to comply, such as children, the elderly, and severely ill patients. Consequently, FeNO detection poses significant challenges for these populations in China, representing a notable clinical gap.\n\nThe newly implemented technology employs an innovative domestic chemiluminescence FeNO analyzer, which is exclusively available in China. This analyzer, owing to its methodological advantages, is capable of obtaining FeNO detection values from patients' natural breathing patterns, facilitating rapid response and comprehensive FeNO assessment without requiring patient cooperation. This approach, referred to as the \"Tidal-breathing of FeNO\" enables the completion of FeNO assessments in patients who are unable to engage in inspiratory and expiratory maneuvers. This advancement is anticipated to enhance the diagnostic accuracy of airway inflammation in this demographic, thereby facilitating early diagnosis, precise treatment, and improved management of disease progression.",[26,397],"Airway Disease",[399,80,400],"FeNO","Tidal breathing","2025-02-25",{"date":403,"type":36},"2025-02-28",{"date":405,"type":36},"2024-09-12",{"date":407,"type":20},"2025-09-01",{"name":409,"class":113},"Novlead Inc.",2,{"id":412,"slug":413,"hasResults":11,"nctId":414,"briefTitle":415,"officialTitle":415,"acronym":4,"eligibilityCriteria":416,"healthyVolunteers":11,"sex":16,"minAge":417,"maxAge":17,"enrollmentInfo":418,"targetDuration":4,"studyType":21,"phases":419,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":144,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":44},"100565097","echo-and-electrocardiographic-findings-in-children-with-bronchial-asthma-at-sohag-university-hospital-100565097","NCT06637748","Echo and Electrocardiographic Findings in Children With Bronchial Asthma At Sohag University Hospital","Inclusion Criteria:\n\n* 1\\. Age range: 5-18 years 2. Confirmed diagnosis of bronchial asthma, made in accordance with current international and national consensus documents\n\nExclusion Criteria:\n\n* . Known congenital heart disease 2. Presence of acute infectious diseases and fever 3. Diabetes 4. Autoimmune disorders 5. Primary immunodeficiency 6. Cancer 7. Current use of oral glucocorticoids 8. Other chronic respiratory conditions 9. Systemic diseases affecting the cardiovascular system","5 Years",{"count":120,"type":20},[23],"Bronchial asthma is a common respiratory disorder among children, worldwide. Asthma is characterized by chronic inflammation and remodeling of the airways induced by recurrent exposure to hypoxemia that leads to repeated tissue injury and repair. The interaction between respiratory diseases and cardiovascular function is complex . Cardiac dysfunction can be attributed to pulmonary hypertension (PH) secondary to recurrent hypoxia in patients with bronchial asthma. PH affects the pulmonary vasculature by releasing various cytokines leading to pulmonary vasoconstriction and enhancing the remodeling process with muscularization and proliferation of the vascular media and intima . Other hypotheses concluded that the exaggerated respiratory efforts may raise the intrathoracic pressure and increase right ventricle (RV) afterload and consequently RV hypertrophy and\u002For dilatation . Children with severe bronchial asthma can experience cor pulmonale later in life, but little is known about the early cardiac changes that might be present during childhood especially for mild or moderate persistent asthma. Some studies have reported right ventricular dysfunction as the earliest hemodynamic change among those cases . Other studies did not report these results and reported impaired systolic function of the left ventricle (LV) even before diastolic dysfunction . Insufficient control of BA, in turn, can cause the formation of various pathological conditions. For example, there are studies showing the risk of cardiac arrhythmias and conduction disorders in patients with uncontrolled BA due to functional changes or pathological remodeling of the myocardium . Atrial remodeling, which is the pathomorphological basis of serious supraventricular cardiac arrhythmias, has a more rapid progression with poor BA control and is formed as a result of excessive stretching of the atrial wall, as well as other adverse factors . The connection between BA and supraventricular arrhythmias, including atrial fibrillation (AF), was noted in studies by Cepelis et al. Available data indicate that in the adult population, cardiac arrhythmias are significantly more common in patients with BA than in those without it (9). The results of a Norwegian population study HUNT study, demonstrate that the risks of supraventricular arrhythmias and AF are increased in patients with an uncontrolled BA . Electrocardiography (ECG) is the universal screening method for assessing the state of the atrial myocardium and the conducting system of the heart. According to German et al. ECG analysis can make a significant input to the assessment of the risk of formation of supraventricular rhythm and conduction disorders. Therefore, the analysis of the atrial component of the ECG, and atrioventricular conduction in patients with BA is an important component of the management of these patients, especially in pediatric practice. Consequently, the study of the characteristics of the ECG and its supraventricular component in children with BA is relevan",[26],"2024-10-10",{"date":424,"type":36},"2024-10-15",{"date":426,"type":20},"2024-10",{"date":428,"type":20},"2025-10",{"name":430,"class":43},"Sohag University",{"id":432,"slug":433,"hasResults":11,"nctId":434,"briefTitle":435,"officialTitle":435,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":52,"sex":16,"minAge":437,"maxAge":161,"enrollmentInfo":438,"targetDuration":4,"studyType":21,"phases":440,"briefSummary":441,"conditions":442,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":44},"100564097","behavioral-changes-among-asthmatic-children-in-sohag-universty-hospital-100564097","NCT06624735","Behavioral Changes Among Asthmatic Children in Sohag Universty Hospital","Inclusion Criteria:\n\nChildren aged 4-12 years Confirmed diagnosed as asthma\n\nExclusion Criteria:\n\nChildren below age of 4 years and aboveage of 12 years . Diagnosed with any other chronic medical conditions (e.g., cardiac , liver , renal and other chronic chest diseases) .\n\nPatient with cerebral palsy.","4 Years",{"count":439,"type":20},100,[23],"Asthma is considered the most common chronic childhood disease and mainly affects children resident in urban areas. Asthma has been designated a serious public health problem due to the increase in its prevalence over the last two decades and the associated high health service costs in admissions and hospitalizations The cause of asthma is not yet completely understood, and there is no consensus about its etiology. A vast body of research emphasizes the role of genetic and environmental factors in the appearance of asthma, and a great deal of interest has recently emerged concerning the relationship between psychosocial factors and asthma morbidity Behavioural problems in children are generally described as \"internalizing\", which includes \"anxiety, depressive, and somatic symptoms\" or \"externalizing\", which includes \"oppositional, hyperactive conduct\". Both internalizing and externalizing problems can be experienced by healthy children with abnormal and \"borderline\" personality disorder, the latter referring to a mental illness marked by an ongoing pattern of varying moods, self-image, and behaviour",[26],"2024-10-02",{"date":445,"type":36},"2024-10-04",{"date":447,"type":36},"2024-07-15",{"date":449,"type":20},"2025-07-15",{"name":430,"class":43},{"id":452,"slug":453,"hasResults":11,"nctId":454,"briefTitle":455,"officialTitle":455,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":457,"enrollmentInfo":458,"targetDuration":4,"studyType":21,"phases":460,"briefSummary":461,"conditions":462,"keywords":463,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":44},"100562959","additive-effects-of-alternative-nostril-breathing-with-pharmacological-management-on-dyspnea-and-control-pause-in-patients-with-bronchial-asthma-100562959","NCT06609941","Additive Effects of Alternative Nostril Breathing with Pharmacological Management on Dyspnea and Control Pause in Patients with Bronchial Asthma","Inclusion Criteria:\n\n* Adults: aged (18-45 years)\n* Gender: Both males and females\n* Grade1- Grade 4 on Modified MRC dyspnea scale\n* Asthma severity classes (intermediate, mild persistent and moderate persistent asthma) acc. to NAEPP national asthma education and prevention program guidlin\n\nExclusion Criteria:\n\n* Patients having acute exacerbation of COPD or status asthmaticus\n* Patients diagnosed with acute infections\n* Patients unable to follow command\u002F instructions\n* Asthma patients with \\>40 sec control pause duration\n* Patients who fall in red zone of asthma action plan (PEFR \\\u003C 50%)","45 Years",{"count":459,"type":20},32,[23],"Bronchial asthma is a widespread chronic condition charactrized by inflammation and narrowing of airways, leading to repeateted episodes of breathlessness, wheezing and labored breathing.Breathing exercises help to manage hyperventilation often seen in asthmatic patients. To handle respiratory complications asthmatics are advised to practise nasal breathing techniques in conjunction with their prescribed medications.",[26],[464],"Dyspnea, asthma control, peak expiratory flow rate","2024-09-20",{"date":467,"type":36},"2024-09-24",{"date":469,"type":36},"2024-06-18",{"date":471,"type":20},"2025-02-01",{"name":473,"class":43},"Foundation University Islamabad",{"id":475,"slug":476,"hasResults":11,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":480,"eligibilityCriteria":481,"healthyVolunteers":11,"sex":16,"minAge":161,"maxAge":482,"enrollmentInfo":483,"targetDuration":4,"studyType":74,"phases":4,"briefSummary":484,"conditions":485,"keywords":486,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":44},"100487821","a-study-of-step-up-in-bronchial-asthma-as-a-new-end-point-in-asthma-control-surfe-100487821","NCT05632081","A Study of Step-up in Bronchial Asthma as a New End Point in Asthma Control (SURFE)","Study of Asthma Step-up in Real Life (SURFE)","SURFE","Inclusion Criteria:\n\n1. Able to give written informed consent.\n2. Age above 12 years.\n3. Ability to use study inhalers correctly, use e-diary, and comply with study procedures and visits.\n4. Confirmed diagnosis of mild or moderate asthma asthma (based on GINA defined asthma control on a maximum of maintenance low dose ICS\u002FLABA combination).\n5. Pre-bronchodilator ≥FEV1 60%.\n6. Reversibility test ≥12% or 200 ml from baseline.\n7. Non-smoker.\n8. For female subjects, non-pregnant and administer efficient contraception if in childbearing period.\n\nExclusion Criteria:\n\n1. Severe asthma exacerbation in last 3 months.\n2. Use of any systemic corticosteroids in last 12 weeks.\n3. Use of depot systemic steroids in last 12 weeks.\n4. Any concurrent respiratory disease as bronchiectasis, COPD, lung fibrosis, …\n5. Current or known history of tuberculosis in any organ.\n6. Current malignancy or any history of malignant disease for the past 5 years.\n7. Subjects receiving any medications with known drug interaction with study medications.\n8. Use of beta-blockers including eye drops.\n9. Any significant concurrent disease as cardiac, hepatic, renal, …\n10. Current or history of alcohol or drug abuse.\n11. Current or history of significant psychiatric disease.\n12. Current or history of significant immunodefieciency.\n13. History of receiving any biological therapy for asthma for the last 3 years or currently eligible for any biological therapy for asthma.\n14. Subjects under any immuno-modulating therapy including biological therapy for any other indication. Subjects may be allowed to participate after 5 times half-live of the concerned drug.\n15. Any known allergy or contraindication to any of the study medications.","80 Years",{"count":439,"type":20},"The goal of this observational study is to learn about the frequency needed for stepping-up treatment in patients with mild and moderate bronchial asthma. The main questions this study aims to answer are:\n\n* What is the frequency and duration in which patients of asthma need to step up their treatment?\n* Can the criteria described in this study be applied and validated to test need for step up of asthma treatment? Participants will follow the treatment they are already receiving according to established guidelines and will be asked for regular visits for examination and spirometry. They will record symptoms score, each time they use the prescribed rescu inhaler, and morning and evening peak expiratory flow.",[26],[80,487,488,489,490,491],"Asthma step-up","Asthma step-down","Asthma exacerbation","Mild asthma","Moderate asthma","2024-09-13",{"date":494,"type":36},"2024-09-19",{"date":496,"type":36},"2024-08-21",{"date":498,"type":20},"2026-03-30",{"name":500,"class":43},"Ain Shams University",{"id":502,"slug":503,"hasResults":11,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":507,"eligibilityCriteria":508,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":509,"enrollmentInfo":510,"targetDuration":4,"studyType":21,"phases":512,"briefSummary":514,"conditions":515,"keywords":516,"overallStatus":144,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":518,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":523,"locationsCount":44},"100559769","phase-4-maintenance-at-initial-treatment-with-sequential-anti-inflammation-reliever-therapy-100559769","NCT06568445","Maintenance at Initial Treatment With Sequential Anti-Inflammation Reliever Therapy","Efficacy of Regular ICS\u002FLABA Sequential As-Needed Therapy in Newly Diagnosed Mild Asthma Patients: A Randomized, Parallel, Positive-Control Study","MIT-AIR","Inclusion Criteria:\n\n1. Participants fully understand the purpose and methods of the study, voluntarily agree to participate, and sign an informed consent form before any study procedures begin.\n2. Adults (including males and non-pregnant, non-lactating females) aged 18 to 70 years (inclusive), who are newly diagnosed with mild and non-acute bronchial asthma according to the latest Chinese guidelines for the prevention and treatment of bronchial asthma.\n3. During the screening period, participants must meet at least one of the following criteria for reversible airflow obstruction: Positive bronchodilator test (increase in FEV1 ≥12% and an absolute increase in FEV1 ≥200 mL after inhaling a bronchodilator). Positive bronchial provocation test (FEV1 decreases by ≥20% after inhalation of the provocation agent methacholine).\n4. At screening and the Day -1 visit before the induction period, participants must have a lung function test showing FEV1 ≥ 80% of the predicted value.\n5. Participants or their guardians must be able to communicate effectively with the researchers, understand, and comply with all requirements of the study.\n\nExclusion Criteria:\n\n1. Individuals allergic or intolerant to budesonide, formoterol, albuterol, or any component of the medication.\n2. Respiratory, sinus, or middle ear infections within the 2 months prior to screening or up to randomization that led to a change in asthma treatment, or are expected to alter the participant's asthma status according to the investigator's judgment.\n3. History of chronic obstructive pulmonary disease (COPD), interstitial lung disease, restrictive lung disease, tuberculosis, cystic fibrosis, bronchiectasis, or alpha-1 antitrypsin deficiency at screening.\n4. History of major diseases at screening, such as congestive heart failure, uncontrolled hypertension, severe coronary artery disease, myocardial infarction, or severe arrhythmias, or severe hematological, hepatic, neurological, musculoskeletal, endocrine, metabolic, psychiatric, renal, or other significant conditions. If any of these conditions worsen during the study, it may endanger the participant or affect study results.\n5. Excessive use of short-acting beta-agonists (SABA), defined as more than 8 inhalations per day, during the screening period and the run-in period.\n6. Use of beta-blockers (including eye drops), oral corticosteroids, systemic steroid treatments, investigational drugs, or leukotriene receptor antagonists (such as zafirlukast, pranlukast, montelukast, etc.) during the run-in period.\n7. History of smoking with a smoking index \\>10 pack-years.\n8. Smoking cessation ≤6 months before the screening visit (Visit 1) or current smokers.\n9. Known or suspected alcohol and\u002For drug abuse, including heavy drinking (average daily consumption \\>2 units of alcohol, where 1 unit = 360 mL of beer, 45 mL of 40% alcohol, or 150 mL of wine).\n10. Abnormal and clinically significant results in vital signs, physical examination, 12-lead ECG, chest CT, blood tests, urinalysis, blood biochemistry, or coagulation tests at screening and the Day -1 visit, unless judged by the investigator to be related to the study condition and not affecting inclusion.\n11. Pregnant or breastfeeding females.\n12. Use of medications that may interact with the study drug within 1 month before screening, such as CYP3A4 inhibitors (e.g., ketoconazole, itraconazole), cimetidine, disulfiram, metronidazole, or CYP3A4 enzyme inducers (e.g., rifampin, carbamazepine, phenytoin).\n13. Participation in other medical device clinical trials within 1 month before screening or other drug clinical trials within 3 months before screening.\n14. Asthma total symptom score (daytime + nighttime) \\\u003C2 points in the week prior to randomization.\n15. Patients who cannot comply with the study procedures or who, in the investigator's judgment, are not suitable for participation in the study.","70 Years",{"count":511,"type":20},90,[513],"PHASE4","1. Evaluate the efficacy of 4 weeks of maintenance therapy with low-dose ICS\u002FLABA versus as-needed low-dose ICS\u002FLABA in newly diagnosed mild asthma patients. Assess the improvement in FEV1 from baseline over 4 weeks, and the impact on airway reversibility and inflammation levels. Identify the optimal patient population and treatment regimen for the medication.\n2. Based on a comprehensive evaluation of pulmonary function parameters (including large airway parameters: FEV1, FEV1\u002FFVC; peak flow: PEF; small airway parameters: FEF25%, FEF50%, FEF75%, MMEF) and airway inflammation levels, explore biomarkers that can effectively predict the efficacy of maintenance therapy with low-dose ICS\u002FLABA in newly diagnosed mild asthma patients.\n3. Compare 4 weeks of initial maintenance therapy with low-dose ICS\u002FLABA followed by as-needed low-dose ICS\u002FLABA therapy until 24 weeks. In the 24-week study, incorporate mobile lung function monitoring to dynamically assess large and small airway function parameters and clinical indicators. Explore the impact of early maintenance therapy with low-dose ICS\u002FLABA followed by as-needed treatment on FEV1 improvement from baseline, acute exacerbation risk indicators, and airway inflammation, and develop a model to predict acute exacerbations.",[26],[249,517],"budesonide-formoterol",{"date":519,"type":36},"2024-08-23",{"date":521,"type":20},"2024-08-12",{"date":278,"type":20},{"name":524,"class":43},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",{"id":526,"slug":527,"hasResults":11,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":4,"eligibilityCriteria":531,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":532,"enrollmentInfo":533,"targetDuration":4,"studyType":74,"phases":4,"briefSummary":534,"conditions":535,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":537,"startDateStruct":539,"completionDateStruct":541,"leadSponsor":543,"locationsCount":44},"100442502","effects-of-pulmonary-diseases-and-their-treatment-on-cardiac-function-100442502","NCT05042219","Effects of Pulmonary Diseases and Their Treatment on Cardiac Function","The Relationship Between Pulmonary and Cardiac Dysfunction and the Cardiac Effects of Pulmonary Treatments: Cardiopulmonary MRI Analysis","Inclusion Criteria:\n\n* Patients with chronic lung disease requiring treatment (COPD, asthma, or pulmonary fibrosis).\n* Age \\> 18 years\n* Informed consent to participate in the study will sign\n\nExclusion Criteria:\n\n* Individuals who are not fully capable of giving consent and understanding the nature, significance and scope of the study.\n* Patients with contraindications to MRI examination (eg, pacemaker, severe claustrophobia) or to contrast medium use (severe renal insufficiency or glomerular filtration rate \\\u003C30 ml\u002Fmin, known gadolinium contrast medium allergy)\n* Patients with atrial fibrillation or other significant cardiac arrhythmias that interfere with cardiac MRI\n* Pregnancy and lactation","99 Years",{"count":237,"type":20},"While the bidirectional relationship between the lung and the right heart are well studied, the cardiopulmonary interactions between the lung and the left heart are largely unresearched and not well understood. However, in recent years, there is a growing evidence that partially explains the bidirectional interaction between COPD and left heart. Systemic inflammation with multiorgan involvement is thought to play a role in COPD as a systemic disease. Some therapeutic approaches to COPD also appear to influence these cardiopulmonary interactions. While understanding these interactions is very important for clinicians, scientific data are scarce. Cardiac magnetic resonance imaging (cardiac MRI) is the gold standard for assessing cardiac function and dimensions as well as myocardial inflammation. Despite this excellent suitability of cardiac MRI for the assessment of cardiovascular function, only few studies have investigated cardiac function and myocardial structure in patients with pulmonary disease using cardiac MRI. Such a study is therefore very important for understanding the effects of pulmonary disease and its management on the heart.\n\nThe objective is to determine cardiac function in patients with pulmonary disease and to analyze the cardiovascular effects of the treatment of the pulmonary disease.\n\nSpecifically, the following will be studied:\n\n* Using cardiac MRI: Cardiac function and volumes and indications of myocardial fibrosis and edema in patients with chronic pulmonary disease at the time of first diagnosis.\n* the vascular function of pulmonary arteries in these patients, also using cardiac MRI\n* the relationship between pulmonary function parameters and cardiac dysfunction to identify patients at increased risk, if applicable.\n* Echocardiographic assessment of left heart including strain analysis.\n* the course of these cardiovascular parameters (using cardiac MRI and echocardiography) 3-6 months after initiation of guideline-based therapy for pulmonary disease.",[217,26,536],"Idiopathic Pulmonary Fibrosis",{"date":538,"type":36},"2024-07-16",{"date":540,"type":36},"2022-06-01",{"date":542,"type":20},"2026-12-14",{"name":544,"class":43},"Ayham Daher",{"id":546,"slug":547,"hasResults":11,"nctId":548,"briefTitle":549,"officialTitle":550,"acronym":4,"eligibilityCriteria":551,"healthyVolunteers":52,"sex":16,"minAge":552,"maxAge":17,"enrollmentInfo":553,"targetDuration":4,"studyType":74,"phases":4,"briefSummary":554,"conditions":555,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":557,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":562,"locationsCount":44},"100552400","risk-of-chronic-kidney-disease-in-bronchial-asthma-100552400","NCT06472596","Risk of Chronic Kidney Disease in Bronchial Asthma","Risk of Developing Chronic Kidney Disease in Patients With Bronchial Asthma at Sohag University Hospitals","Inclusion Criteria:\n\n* all children diagnosed as bronchial asthma at sohag university hospitals from age of 2 years to age of 18 years and donot have any associated disease\n\nExclusion Criteria:\n\n* persons who have any chronic illness persons who have any associated disease with bronchial asthma persons who missing clinical and laboratory investigations persons who refusing to give written informed consent for the study","2 Years",{"count":439,"type":20},"the study aims to determine the frequency and factors associated with chronic kidney disease among asthmatic patients in order to determine persons who are at risk of developing chronic kidney disease and require strict follow up in long run , to evaluate severity of asthma as a potential risk for developing kidney injury , to evaluate relationship between different inflammatory markers with severity of asthma and risk of deneloping chronic kidney disease",[26],"2024-06-24",{"date":558,"type":36},"2024-06-25",{"date":560,"type":36},"2024-06-01",{"date":252,"type":20},{"name":430,"class":43},{"id":564,"slug":565,"hasResults":11,"nctId":566,"briefTitle":567,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":482,"enrollmentInfo":569,"targetDuration":4,"studyType":74,"phases":4,"briefSummary":571,"conditions":572,"keywords":573,"overallStatus":144,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":44},"100544807","respiratory-disease-cohort-studies-of-chinese-medicine-for-asthma-research--asthma-100544807","NCT06373692","REspiratory diSEAse cohoRt Studies of CHinese Medicine for Asthma (RESEARCH- Asthma)","Inclusion Criteria:\n\n1. Patients who meet the diagnosis of bronchial asthma;\n2. Age 18\\~80 years old;\n3. Have not participated in other clinical studies within 1 month before enrollment;\n4. Voluntarily participate in the study and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with respiratory failure and mechanical ventilation during acute asthma exacerbation;\n2. Delirium, impaired consciousness, dementia, and various mental illnesses;\n3. Patients with other lung diseases such as COPD, lung abscess, cystic fibrosis, bronchiectasis, etc., and severe liver and kidney diseases;\n4. Patients with neuromuscular diseases that affect respiratory motor function and are unable to complete the six-minute walk test;\n5. Pregnant and lactating patients;\n6. Those who are participating in other clinical trials.",{"count":570,"type":20},1508,"The purpose of this study is to define the standard use of TCM treatment regimen as the TCM cohort group and the non-TCM cohort group of those who use conventional Western medicine treatment without the standard TCM treatment regimen through a multi-center, large-sample prospective cohort study design. To evaluate the clinical efficacy and safety of TCM treatment regimens in the treatment of bronchial asthma, and to provide high-quality evidence for the promotion and application of TCM syndrome differentiation treatment in bronchial asthma.",[26],[80,574,575,576],"Asthma control rate","Number of acute attacks","Cohort studies","2024-04-15",{"date":579,"type":36},"2024-04-18",{"date":581,"type":20},"2024-05-01",{"date":583,"type":20},"2026-12-30",{"name":42,"class":43}]